Home » USA Broker Ratings » Vertex Pharmaceuticals Incorpor – Consenus Indicates Potential 14.3% Upside

Vertex Pharmaceuticals Incorpor – Consenus Indicates Potential 14.3% Upside

Vertex Pharmaceuticals Incorpor with ticker code (VRTX) now have 20 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 285 and 200 with a mean TP of 228. Given that the stocks previous close was at 199.42 this would indicate that there is a potential upside of 14.3%. The 50 day moving average now sits at 179.96 while the 200 day moving average is 176.38. The market cap for the company is $49,295m. You can visit the company’s website by visiting: http://www.vrtx.com

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics, as well as a strategic collaboration with Ribometrix, Inc. to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.